Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02193113 · ClinicalTrials.gov registry record · Phase 1
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
A Phase 1 study of Diabetic Macular Edema, sponsored by KalVista Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 5
- Study locations
NCT02193113 is a Phase 1 study of Diabetic Macular Edema that has completed, run by KalVista Pharmaceuticals. The registered enrollment target is 14 participants, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (100% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT02193113, a Phase 1 study of Diabetic Macular Edema, has completed, sponsored by KalVista Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a Phase 1 study to investigate the safety, tolerability of the novel plasma kallikrein inhibitor, KVD001 in subjects with diabetic macular edema. The study is the first step to investigate the hypothesis that plasma kallikrein plays an important role in the disease process behind diabetic macular edema in many patients
Conditions Studied
Interventions
- DRUG KVD001 Injection
Study Locations (5)
California
- Retina Vitreous Associates Medical Group - Beverly Hills
Indiana
- Raj K. Maturi, MD PC - Indianapolis
Massachusetts
- Beetham Eye Institute - Boston
South Carolina
- Palmetto Retina Center - West Columbia
Texas
- Valley Retina Institute, PA - McAllen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2014-07-18 |
| Est. Completion | 2015-06-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02193113
The ClinicalTrials.gov registry entry for NCT02193113 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (100% lower). The listed sponsor is KalVista Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Macular Edema appearing as the primary indexed condition, and to 1 intervention - of which KVD001 Injection is the first listed.
NCT02193113 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Indiana, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02193113 about?
NCT02193113 is a clinical study titled "A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME". This is a Phase 1 study to investigate the safety, tolerability of the novel plasma kallikrein inhibitor, KVD001 in subjects with diabetic macular edema. The study is the first step to investigate the hypothesis that plasma kallikrein plays an important role in the disease process behind diabetic ma...
What is the current status of trial NCT02193113?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2014-07-18. Estimated completion is 2015-06-04.
What conditions does trial NCT02193113 study?
This clinical trial studies the following conditions: Diabetic Macular Edema.
What interventions are being tested in trial NCT02193113?
The interventions under investigation include: KVD001 Injection (DRUG).
Who is sponsoring clinical trial NCT02193113?
This trial is sponsored by KalVista Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02193113 being conducted?
This trial has 5 study locations across California, Indiana, Massachusetts, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
RECRUITING · Phase 1
-
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
RECRUITING · Phase 1
-
Kamuvudine-9 (K9) in Diabetic Macular Edema
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.